Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules As Potential Disease Modifying Therapeutics for Parkinson's Disease

K. Kelly,J. Meredith, L. Kimmel, S. Sparks, A. DeSantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan,G. Cadelina,J. Pizzano, A. Cacace

MOVEMENT DISORDERS（2023）

Cited 0|Views9

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined